ZTS250117P120000
- 0.15
- 0.000.00%
Zoetis Newsroom
Zoetis Inc. (ZTS): A Bull Case Theory
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Here's Why Zoetis (ZTS) Gained But Lagged the Market Today
Earnings Are Growing at Zoetis (NYSE:ZTS) but Shareholders Still Don't Like Its Prospects
Leerink Partners Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $215
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Walgreens Boots Alliance (WBA) and Bicycle Therapeutics (BCYC)
Zoetis Dips as FDA Cites Adverse Events Linked to Canine Pain Therapy Librela
FDA Warns About Dangers of Dog Pain Drug -- WSJ
BofA Securities Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $210
Positive Outlook on Zoetis's Stock Despite FDA Review of Librela
4 Stocks in Focus That Declared Dividend Hikes Amid Market Volatility
Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Recent Dividend Declarations
Zoetis To Go Ex-Dividend On January 21st, 2025 With 0.5 USD Dividend Per Share
December 12th (Eastern Time) - $Zoetis(ZTS.US)$ is trading ex-dividend on January 21st, 2025.Shareholders of record on January 21st, 2025 will receive 0.5 USD dividend per share on March 4th, 2025.
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Zoetis Raises Dividend to 50c >ZTS
Press Release: Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase
Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase
Why Zoetis Inc. (NYSE:ZTS) Looks Like A Quality Company
Zoetis Initiated With a Neutral at UBS